Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them ...